Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 2/20 | 0.71 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.50 |
| ▸ | ACP3 | P15309 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6660390 | 0.87 | MIF (0.67) | MIFGRIN2BACP3TAAR1IDO1 | |
| SCHEMBL7469794 | 0.83 | MIF (0.72) | MIFACP3TAAR1IDO1HTR2A | |
| SCHEMBL2340843 | 0.83 | MIF (1.00) | MIFGRIN2BACP3TAAR1IDO1 | |
| SCHEMBL7079916 | 0.83 | MIF (0.71) | MIFGRIN2BACP3TAAR1IDO1 | |
| SCHEMBL2906765 | 0.83 | MIF (0.49) | MIFGRIN2B | |
| SCHEMBL29129683 | 0.82 | MIF (0.46) | MIFGRIN2BIDO1DAO | |
| SCHEMBL28872903 | 0.82 | MIF (0.49) | MIFGRIN2BGRIN1MAPT | |
| SCHEMBL26785 | 0.81 | MIF (0.47) | MIFGRIN2BTAAR1LMNAGRIN1 | |
| SCHEMBL5465655 | 0.81 | MIF (0.47) | MIFGRIN2BTAAR1LMNAGRIN1 | |
| SCHEMBL6662002 | 0.80 | MIF (0.77) | MIFGRIN2BACP3TAAR1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122059940-A | Mountain lotus leaf essence urea derivative and preparation method and application thereof | 南通大学 | 2026-05-19 | — | — | CN | disclosed |
| EP-4735422-A1 | SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF TREATING PHENYLKETONURIA AND OTHER AMINO ACIDURIAS | Sanofi (FR) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025006827-A1 | SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF TREATING PHENYLKETONURIA AND OTHER AMINO ACIDURIAS | GENZYME CORPORATION (US) | 2025-01-02 | — | — | WO | disclosed |
| CN-115109019-B | Dehydrocostuslactone derivative, and preparation method and application thereof | 上海医药工业研究院 | 2024-02-02 | — | — | CN | disclosed |
| EP-4143165-A1 | SPIROUREA DERIVATIVES | Idorsia Pharmaceuticals Ltd (CH) | 2023-03-08 | — | — | EP | disclosed |
| CN-115702141-A | Cyclobutyl-urea derivatives | 爱杜西亚药品有限公司 | 2023-02-14 | — | — | CN | disclosed |
| CN-115461327-A | Spiro urea derivatives | 爱杜西亚药品有限公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-115109019-A | Dehydrocostuslactone derivative, preparation method and application thereof | 上海医药工业研究院 | 2022-09-27 | — | — | CN | disclosed |
| EP-3559005-A1 | THIENOPYRROLE DERIVATIVES FOR USE IN TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | Biotheryx Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018118947-A1 | THIENOPYRROLE DERIVATIVES FOR USE IN TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20170273922-A1 | UREA AND BIS-UREA BASED COMPOUNDS AND ANALOGUES THEREOF USEFUL IN THE TREATMENT OF ANDROGEN RECEPTOR MEDIATED DISEASES OR DISORDERS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2017-09-28 | — | — | US | disclosed |
| EP-3201174-A1 | UREA AND BIS-UREA BASED COMPOUNDS AND ANALOGUES THEREOF USEFUL IN THE TREATMENT OF ANDROGEN RECEPTOR MEDIATED DISEASES OR DISORDERS | The Royal Institution for the Advancement of Learning / McGill University (CA) | 2017-08-09 | — | — | EP | disclosed |
| WO-2016049774-A1 | UREA AND BIS-UREA BASED COMPOUNDS AND ANALOGUES THEREOF USEFUL IN THE TREATMENT OF ANDROGEN RECEPTOR MEDIATED DISEASES OR DISORDERS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2016-04-07 | — | — | WO | disclosed |
| EP-2379519-A1 | (4-TERT-BUTYLPIPERAZIN-2-YL)(PIPERAZIN-1-YL)METHANONE-N-CARBOXAMIDE DERIVATIVES | AstraZeneca AB (SE) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010071567-A1 | (4-TERT-BUTYLPIPERAZIN-2-YL)(PIPERAZIN-1-YL)METHANONE-N-CARBOXAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | WO | disclosed |
| EP-1828186-A1 | PYRIDO PYRIMIDINONES, DIHYDRO PYRIMIDO PYRIMIDINONES AND PTERIDINONES USEFUL AS RAF KINASE INHIBITORS | Sunesis Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2007024294-A2 | CERTAIN SUBSTITUTED UREAS, AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2006065703-A1 | PYRIDO PYRIMIDINONES, DIHYDRO PYRIMIDO PYRIMIDINONES AND PTERIDINONES USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| US-6248765-B1 | ANTIINFLAMMATORY AGENTS; HYPOTENSIVE AGENTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICAL (FR) | 2001-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170273922-A1 | UREA AND BIS-UREA BASED COMPOUNDS AND ANALOGUES THEREOF USEFUL IN THE TREATMENT OF ANDROGEN RECEPTOR MEDIATED DISEASES OR DISORDERS | AR, UTS2R, SHBG | MIF 4820/4885GRIN2B 2498/4885ACP3 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.